Royalty Pharma and Cytokinetics Announce Expanded Strategic
Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN FRANCISCO,...
Source: globenewswire.com
Roberti Blum News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Roberti Blum. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Roberti Blum Today - Breaking & Trending Today
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
22.05.2024 - Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) - Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, ... Seite 1
Source: wallstreet-online.de
Needham & Company LLC Reaffirms Buy Rating for Cytokinetics (NASDAQ:CYTK)
Needham & Company LLC reissued their buy rating on shares of Cytokinetics (NASDAQ:CYTK – Free Report) in a research report released on Tuesday morning, Benzinga reports. The firm currently has a $108.00 price objective on the biopharmaceutical company’s stock. Other equities analysts also recently issued reports about the company. Oppenheimer reiterated an outperform rating and […]
Source: etfdailynews.com
HC Advisors LLC Invests $271,000 in Cytokinetics, Incorporated (NASDAQ:CYTK)
HC Advisors LLC acquired a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 3,243 shares of the biopharmaceutical company’s stock, valued at approximately $271,000. Other institutional investors and hedge […]
Source: modernreaders.com
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) has received a consensus rating of “Moderate Buy” from the fifteen research firms that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 1 year target […]
Source: wkrb13.com